Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05952856 · ClinicalTrials.gov registry record · Phase 3
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,912
- Enrollment target
NCT05952856 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 2,912 participants.
The verdict
NCT05952856, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,912 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.
Interventions
- DRUG Placebo
- DRUG Enlicitide Decanoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,912 participants |
| Start Date | 2023-08-10 |
| Est. Completion | 2025-07-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05952856
The ClinicalTrials.gov registry entry for NCT05952856 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,912 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05952856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05952856 about?
NCT05952856 is a clinical study titled "A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids". The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol...
What is the current status of trial NCT05952856?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,912 participants. The study started on 2023-08-10. Estimated completion is 2025-07-28.
What interventions are being tested in trial NCT05952856?
The interventions under investigation include: Placebo (DRUG), Enlicitide Decanoate (DRUG).
Who is sponsoring clinical trial NCT05952856?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.